查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1877439

抗感染藥物市場：依藥物類別、適應症、給藥途徑、最終用戶、國家及地區分類－全球產業分析、市場規模、市場佔有率及2025-2032年預測

Anti-Infective Drugs Market, By Drug Class, By Indication, By Route of Administration, By End-User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 378 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2024 年抗感染藥物市場規模價值為 1,342.6721 億美元，從 2025 年到 2032 年以 3.1% 的複合年成長率成長。

抗感染藥物市場專注於研發和分銷用於預防和治療細菌、病毒、真菌和寄生蟲感染的藥物。醫院感染率的上升和抗生素抗藥性的日益嚴重，促使輝瑞和葛蘭素史克等製藥公司擴大其新型抗菌藥物的研發管線。例如，世界衛生組織報告稱，2023年有超過495萬人死於抗藥性感染，這使得對先進療法的需求變得迫切。生技公司與學術界的合作正在推動下一代抗生素和抗病毒藥物的研發。然而，抗生素的高昂研發成本和不斷下降的利潤阻礙了小型企業進入市場。新興經濟體治療途徑的擴大以及對聯合療法的日益重視，為企業提供了產品組合多元化和改善患者療效的機會。

抗感染藥物市場－市場動態

感染負擔加重和抗菌素抗藥性加劇推動抗感染藥物創新

感染率上升和抗菌素抗藥性日益嚴重，正促使全球衛生機構和製藥公司加速抗感染藥物的創新。根據世界衛生組織統計，抗菌素抗藥性每年直接導致127萬人死亡，另有368萬人死於抗藥性感染。這促使美國疾病管制與預防中心（CDC）等機構資助快速診斷工具和新型抗生素的研發計畫。各國政府也支持公私合作項目，例如抗菌素抗藥性行動基金，以因應抗生素研發管線日益萎縮的問題。這些努力正在推動新型抗菌藥物、標靶抗病毒藥物和聯合療法的研發，以更有效地對抗抗藥性病原體。

抗感染藥物市場細分分析：

全球抗感染藥物市場按藥物類別、適應症、給藥途徑、最終用戶和地區進行細分。

根據藥物類別，市場可分為四大類：抗菌藥、抗黴菌藥、抗寄生蟲藥和抗病毒藥。抗菌藥物佔據最大市場佔有率，這主要得益於細菌感染治療的廣泛應用；其次是抗病毒藥，這主要受病毒爆發日益增多的推動；抗真菌藥物緊隨其後，這主要與侵襲性真菌感染發病率的上升有關；而抗寄生蟲藥雖然市場佔有率較小，但在全球範圍內卻佔據著至關重要的地位。

根據適應症，市場分為九大類：肺炎、敗血症、結核病、皮癬菌病、念珠菌病、肝炎病毒感染、HIV感染、新冠病毒感染和抗甲氧西林金黃色葡萄球菌感染。肺炎因其全球負擔沉重而位居榜首，其次是敗血症，因為重症監護需求不斷增加。 HIV感染和肝炎感染佔據較大佔有率，且治療項目仍在進行中，而結核病和耐甲氧西林金黃色葡萄球菌感染則推動了抗生素的研發。念珠菌病、皮癬菌病和新冠病毒感染是重點治療領域。

抗感染藥物市場—地域洞察

北美憑藉強大的醫療基礎設施以及輝瑞和默克等企業持續的研發投入，在抗感染藥物市場佔據領先地位。 2018年，輝瑞與BioNTech合作，將基於mRNA的抗感染藥物的應用範圍拓展至新冠肺炎以外的領域，從而鞏固了其在北美的市場地位。歐洲緊隨其後，這得益於歐盟資助的抗菌素抗藥性（AMR）計畫以及葛蘭素史克與生物醫學高級研究與發展局（BARDA）合作開發新型抗生素等合作計畫。亞太地區正崛起為重要的成長中心，這主要得益於不斷上升的感染率以及各國政府為改善治療可及性所做的努力；例如，印度的國家抗菌素抗藥性行動計劃提倡合理使用抗生素和本地化生產。拉丁美洲和中東及非洲地區的疫苗接種率不斷提高，公共健康宣傳活動也日益活躍。

抗感染藥物市場—國家洞察

美國憑藉先進的醫療保健體系和強大的臨床試驗計畫儲備，在北美抗感染藥物市場佔據主導地位。 2024年，默克公司收購了Prometheus Biosciences公司，以增強其免疫學和傳染病產品組合，並提升其研發能力。美國政府的生物醫學高級研究與發展局（BARDA）持續資助與葛蘭素史克（GSK）和Venatorx Pharmaceuticals等公司的合作，以加速抗生素的研發。美國疾病管制與預防中心（CDC）報告的多重抗藥性感染病例不斷增加，促使醫院採用更新的療法和診斷工具。美國食品藥物管理局（FDA）強力的監管框架以及《全球抗感染藥物創新法案》（GAIN Act）等激勵措施進一步促進了新型抗感染藥物的創新和商業化。

抗感染藥物市場－競爭格局：

抗感染藥物市場的競爭格局由輝瑞、默克、葛蘭素史克、強生和羅氏等產業領導者主導，這些企業正透過研發和策略交易不斷拓展產品線。 2020年，輝瑞與吉利德科學公司合作，共同開發針對抗藥性感染的新型抗病毒組合藥物。葛蘭素史克與美國生物醫學高級研究與發展局（BARDA）的合作支持下一代抗生素的研發，而強生則投資於噬菌體研究以對抗超級細菌。像Venatorx Pharmaceuticals和Iterum Therapeutics這樣的小型生物技術公司正與大型製藥公司合作，以擴大生產和分銷規模。這種合作、收購和政府支援項目的組合正在加劇競爭，並加速藥物創新。

目錄

第1章：抗感染藥物市場概覽

  • 研究範圍
  • 市場估算年份

第2章：執行概要

  • 市集
    • 抗感染藥物市場概況（按藥物類別分類）
    • 抗感染藥物市場概況（依適應症分類）
    • 抗感染藥物市場概況（依給藥途徑分類）
    • 抗感染藥物市場按最終用戶分類的概況
    • 各國抗感染藥物市場概況
    • 抗感染藥物市場概況（按地區分類）
  • 競爭洞察

第3章：抗感染藥物市場主要趨勢

  • 抗感染藥物市場促進因素
    • 市場促進因素的影響分析
  • 抗感染藥物市場限制因素
    • 市場限制因素的影響分析
  • 抗感染藥物市場機遇
  • 抗感染藥物市場未來趨勢

第4章：抗感染藥物產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景分析
  • 規範架構分析

第5章：抗感染藥物市場：地緣政治緊張局勢升級的影響

  • 新冠疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：抗感染藥物市場概況

  • 抗感染藥物市佔率分析，2024年
  • 主要製造商細分數據
    • 知名球員分析
    • 新興參與者分析

第7章：抗感染藥物市場－依藥物類別分類

  • 概述
    • 按藥物類別分類的細分市場佔有率分析
    • 抗菌
      • BETA-內醯胺類抗生素
      • 奎諾酮類
      • 大環內酯類
      • 四環素
      • 氨基糖苷類
      • 其他
    • 抗真菌藥物
      • 唑類
      • 棘白菌素
      • 多烯類
    • 抗寄生蟲藥
    • 抗病毒藥物

第8章：抗感染藥物市場－依適應症分類

  • 概述
    • 按指標分類的細分市場佔有率分析
    • 肺炎
    • 敗血症
    • 結核
    • 皮癬菌病
    • 念珠菌病
    • 肝炎病毒感染
    • 愛滋病毒感染
    • 嚴重特殊傳染性肺炎病毒
    • 抗甲氧西林金黃色葡萄球菌
    • 其他

第9章：抗感染藥物市場－依給藥途徑分類

  • 概述
    • 按給藥途徑分類的細分市佔率分析
    • 口服
    • 注射劑
    • 主題
    • 吸入

第10章：抗感染藥物市場－以最終用戶分類

  • 概述
    • 按最終用戶分類的細分市場佔有率分析
    • 醫院
    • 診所
    • 零售藥局
    • 機構買家

第11章：抗感染藥物市場－依地域分類

  • 介紹
    • 按地域分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美抗感染藥物主要生產商
    • 北美市場規模及預測（按國家/地區分類）
    • 北美市場規模及預測（按藥物類別分類）
    • 北美市場規模及預測（依適應症分類）
    • 北美市場規模及預測（依給藥途徑分類）
    • 北美市場規模及預測（依最終用戶分類）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲抗感染藥物主要生產商
    • 歐洲市場規模及預測（按國家/地區分類）
    • 歐洲市場規模及預測（按藥物類別分類）
    • 歐洲市場規模及預測（依適應症分類）
    • 歐洲市場規模及預測（依給藥途徑分類）
    • 歐洲市場規模及預測（依最終用戶分類）
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 歐洲其他地區
  • 亞太地區
    • 概述
    • 亞太地區抗感染藥物主要生產商
    • 亞太市場規模及預測（依國家/地區分類）
    • 亞太地區市場規模及預測（依藥物類別分類）
    • 亞太地區市場規模及預測（依適應症分類）
    • 亞太地區市場規模及預測（依給藥途徑分類）
    • 亞太市場規模及預測（依最終用戶分類）
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 亞太其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲抗感染藥物主要生產商
    • 拉丁美洲市場規模及預測（按國家/地區分類）
    • 拉丁美洲市場規模及預測（按藥物類別分類）
    • 拉丁美洲市場規模及預測（依適應症分類）
    • 拉丁美洲市場規模及預測（依給藥途徑分類）
    • 拉丁美洲市場規模及預測（按最終用戶分類）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲（MEA）
    • 概述
    • 中東和非洲抗感染藥物主要生產商
    • MEA市場規模及預測（依國家/地區分類）
    • MEA市場規模及預測（依藥物類別分類）
    • MEA市場規模及預測（依適應症分類）
    • MEA市場規模及預測（依給藥途徑分類）
    • MEA市場規模及預測（依最終用戶分類）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • 中東和非洲其他地區

第12章：主要供應商分析－抗感染藥物產業

  • 競爭格局分析
    • Competitive Benchmarking
    • Competitive Positioning
  • 公司簡介
    • AbbVie
    • AstraZeneca
    • Bayer
    • Cipla
    • Dr. Reddy's Laboratories
    • Gilead Sciences
    • GlaxoSmithKline (GSK)
    • Glenmark Pharmaceuticals
    • Johnson & Johnson
    • Lupin
    • Merck & Co.
    • Novartis
    • Pfizer
    • Roche
    • Sandoz (Novartis)
    • Sanofi
    • Sun Pharmaceutical Industries
    • Teva Pharmaceutical Industries
    • Viatris
    • ViiV Healthcare
    • Others

第13章：360度AnalystView

第14章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV5742

The Anti-Infective Drugs Market size was valued at US$ 134,267.21 Million in 2024, expanding at a CAGR of 3.1% from 2025 to 2032.

The anti-infective drugs market focuses on the development and distribution of medications used to prevent and treat infections caused by bacteria, viruses, fungi, and parasites. The rising incidence of hospital-acquired infections and increasing antibiotic resistance have pushed pharmaceutical companies like Pfizer and GlaxoSmithKline to expand their R&D pipelines for novel antimicrobials. For example, the WHO reported that over 4.95 million deaths in 2023 were linked to drug-resistant bacterial infections, creating urgent demand for advanced therapies. Partnerships between biotech firms and academia are supporting the development of next-generation antibiotics and antivirals. However, high development costs and declining profitability of antibiotics discourage smaller players from entering the market. Expanding access to treatments in emerging economies and the rising focus on combination therapies present opportunities for companies to diversify product portfolios and improve patient outcomes.

Anti-Infective Drugs Market- Market Dynamics

Rising Infection Burden and Antimicrobial Resistance Fuel Innovation in Anti-Infective Drugs

Rising infection rates and growing antimicrobial resistance are pushing global health agencies and pharmaceutical companies to accelerate innovation in anti-infective drugs. According to the WHO, antimicrobial resistance was responsible for 1.27 million direct deaths a year, with an additional 3.68 million deaths associated with drug-resistant infections. This has led organizations like the U.S. Centers for Disease Control and Prevention (CDC) to fund initiatives for rapid diagnostic tools and novel antibiotics. Governments are also supporting public-private partnerships, such as the AMR Action Fund, to address the dwindling antibiotic pipeline. These efforts are encouraging the development of new classes of antimicrobials, targeted antivirals, and combination therapies to combat resistant pathogens more effectively.

Anti-Infective Drugs Market- Segmentation Analysis:

The Global Anti-Infective Drugs Market is segmented on the basis of Drug Class, Indication, Route of Administration, End-User, and Region.

The market is divided into four categories based on Drug Class: Antibacterial, Antifungals, Antiparasitic, and Antivirals. Antibacterials hold the highest share due to widespread bacterial infection treatments, followed by antivirals driven by rising viral outbreaks. Antifungals rank next with the growing incidence of invasive fungal infections, while antiparasitics represent a smaller but crucial niche segment globally.

The market is divided into nine categories based on Indication: Pneumonia, Sepsis, Tuberculosis, Dermatophytosis, Candidiasis, Hepatitis virus infection, HIV infection, Covid-19 Virus, and Methicillin-resistant Staphylococcus Aureus. Pneumonia leads due to its high global burden, followed by sepsis, as critical care demand rises. HIV and hepatitis infections hold strong shares with ongoing treatment programs, while tuberculosis and MRSA drive antibiotic development. Candidiasis, dermatophytosis, and COVID-19 represent targeted therapeutic segments.

Anti-Infective Drugs Market- Geographical Insights

North America leads the anti-infective drugs market due to strong healthcare infrastructure and continuous R&D investments by players like Pfizer and Merck. In 2018, Pfizer collaborated with BioNTech to expand mRNA-based anti-infective applications beyond COVID-19, strengthening its regional presence. Europe follows closely, supported by EU-funded antimicrobial resistance (AMR) programs and partnerships like GSK's collaboration with BARDA to develop new antibiotics. Asia-Pacific is emerging as a key growth hub, driven by rising infection rates and government efforts to improve access to treatments; for instance, India's National Action Plan on AMR promotes antibiotic stewardship and local production. Latin America and MEA witness growing vaccine adoption and public health campaigns.

Anti-Infective Drugs Market- Country Insights

The United States dominates the North American anti-infective drugs market, supported by advanced healthcare systems and a robust pipeline of clinical trials. In 2024, Merck acquired Prometheus Biosciences to strengthen its immunology and infectious disease portfolio, enhancing its research capabilities. The U.S. government's Biomedical Advanced Research and Development Authority (BARDA) continues funding collaborations with companies like GSK and Venatorx Pharmaceuticals to accelerate antibiotic development. Rising cases of multidrug-resistant infections reported by the CDC are prompting hospitals to adopt newer therapies and diagnostic tools. Strong regulatory frameworks from the FDA and incentives like the GAIN Act further encourage innovation and commercialization of novel anti-infectives.

Anti-Infective Drugs Market- Competitive Landscape:

The competitive landscape of the anti-infective drugs market is shaped by leading players such as Pfizer, Merck, GSK, Johnson & Johnson, and Roche, who are expanding portfolios through R&D and strategic deals. In 2020, Pfizer partnered with Gilead Sciences to co-develop new antiviral combinations targeting resistant infections. GSK's collaboration with BARDA supports the development of next-generation antibiotics, while Johnson & Johnson invests in bacteriophage research to combat superbugs. Smaller biotech firms like Venatorx Pharmaceuticals and Iterum Therapeutics are entering collaborations with big pharma to scale manufacturing and distribution. This mix of partnerships, acquisitions, and government-backed programs is intensifying competition and accelerating drug innovation.

Recent Developments:

In February 2025, the Merieux Foundation, SPIM, and WHO launched a new Guide to Prescribing Anti-infective Drugs in Madagascar, updating antibiotic chapters, diagnostics, and integrating WHO's 2023 AWaRe classification to support standardized prescribing and strengthen national AMR action plans.

In February 2025, the U.S. FDA approved EMBLAVEO(TM) (aztreonam + avibactam) for adult patients with complicated intra-abdominal infections when few or no treatment options exist, including infections by E. coli and Klebsiella.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ANTI-INFECTIVE DRUGS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • AbbVie
  • AstraZeneca
  • Bayer
  • Cipla
  • Dr. Reddy's Laboratories
  • Gilead Sciences
  • GlaxoSmithKline (GSK)
  • Glenmark Pharmaceuticals
  • Johnson & Johnson
  • Lupin
  • Merck & Co.
  • Novartis
  • Pfizer
  • Roche
  • Sandoz (Novartis)
  • Sanofi
  • Sun Pharmaceutical Industries
  • Teva Pharmaceutical Industries
  • Viatris
  • ViiV Healthcare
  • Others

GLOBAL ANTI-INFECTIVE DRUGS MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • Antibacterial
  • B-Lactams
  • Quinolones
  • Macrolides
  • Tetracycline
  • Aminoglycoside
  • Others
  • Antifungals
  • Azoles
  • Echinocandins
  • Polyenes
  • Antiparasitics
  • Antivirals

GLOBAL ANTI-INFECTIVE DRUGS MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Pneumonia
  • Sepsis
  • Tuberculosis
  • Dermatophytosis
  • Candidiasis
  • Hepatitis virus infection
  • HIV infection
  • Covid-19 Virus
  • Methicillin-resistant Staphylococcus Aureus
  • Others

GLOBAL ANTI-INFECTIVE DRUGS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Injectable
  • Topical
  • Inhalation

GLOBAL ANTI-INFECTIVE DRUGS MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Clinics
  • Retail Pharmacies
  • Institutional Buyers

GLOBAL ANTI-INFECTIVE DRUGS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Anti-Infective Drugs Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Anti-Infective Drugs Market Snippet by Drug Class
    • 2.1.2. Anti-Infective Drugs Market Snippet by Indication
    • 2.1.3. Anti-Infective Drugs Market Snippet by Route of Administration
    • 2.1.4. Anti-Infective Drugs Market Snippet by End-User
    • 2.1.5. Anti-Infective Drugs Market Snippet by Country
    • 2.1.6. Anti-Infective Drugs Market Snippet by Region
  • 2.2. Competitive Insights

3. Anti-Infective Drugs Key Market Trends

  • 3.1. Anti-Infective Drugs Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Anti-Infective Drugs Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Anti-Infective Drugs Market Opportunities
  • 3.4. Anti-Infective Drugs Market Future Trends

4. Anti-Infective Drugs Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Anti-Infective Drugs Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Anti-Infective Drugs Market Landscape

  • 6.1. Anti-Infective Drugs Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Anti-Infective Drugs Market - By Drug Class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Class, 2024 & 2032 (%)
    • 7.1.2. Antibacterial
      • 7.1.2.1. B-Lactams
      • 7.1.2.2. Quinolones
      • 7.1.2.3. Macrolides
      • 7.1.2.4. Tetracycline
      • 7.1.2.5. Aminoglycoside
      • 7.1.2.6. Others
    • 7.1.3. Antifungals
      • 7.1.3.1. Azoles
      • 7.1.3.2. Echinocandins
      • 7.1.3.3. Polyenes
    • 7.1.4. Antiparasitics
    • 7.1.5. Antivirals

8. Anti-Infective Drugs Market - By Indication

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Indication, 2024 & 2032 (%)
    • 8.1.2. Pneumonia
    • 8.1.3. Sepsis
    • 8.1.4. Tuberculosis
    • 8.1.5. Dermatophytosis
    • 8.1.6. Candidiasis
    • 8.1.7. Hepatitis virus infection
    • 8.1.8. HIV infection
    • 8.1.9. Covid-19 Virus
    • 8.1.10. Methicilin-resistant Staphylococcus Aureus
    • 8.1.11. Others

9. Anti-Infective Drugs Market - By Route of Administration

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Route of Administration, 2024 & 2032 (%)
    • 9.1.2. Oral
    • 9.1.3. Injectable
    • 9.1.4. Topical
    • 9.1.5. Inhalation

10. Anti-Infective Drugs Market - By End-User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End-User, 2024 & 2032 (%)
    • 10.1.2. Hospitals
    • 10.1.3. Clinics
    • 10.1.4. Retail Pharmacies
    • 10.1.5. Institutional Buyers

11. Anti-Infective Drugs Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Anti-Infective Drugs Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Anti-Infective Drugs Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.17. Rest of Europe
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.17.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.17.6. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Anti-Infective Drugs Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Anti-Infective Drugs Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. Anti-Infective Drugs Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Anti-Infective Drugs Industry

  • 12.1. Competitive Dashboard
    • 12.1.1. Competitive Benchmarking
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. AbbVie
    • 12.2.2. AstraZeneca
    • 12.2.3. Bayer
    • 12.2.4. Cipla
    • 12.2.5. Dr. Reddy's Laboratories
    • 12.2.6. Gilead Sciences
    • 12.2.7. GlaxoSmithKline (GSK)
    • 12.2.8. Glenmark Pharmaceuticals
    • 12.2.9. Johnson & Johnson
    • 12.2.10. Lupin
    • 12.2.11. Merck & Co.
    • 12.2.12. Novartis
    • 12.2.13. Pfizer
    • 12.2.14. Roche
    • 12.2.15. Sandoz (Novartis)
    • 12.2.16. Sanofi
    • 12.2.17. Sun Pharmaceutical Industries
    • 12.2.18. Teva Pharmaceutical Industries
    • 12.2.19. Viatris
    • 12.2.20. ViiV Healthcare
    • 12.2.21. Others

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us